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Abstract: Alcohol consumption during pregnancy and its damaging consequences on the developing
infant brain are significant public health, social, and economic issues. The major distinctive features
of prenatal alcohol exposure in humans are cognitive and behavioral dysfunction due to damage to
the central nervous system (CNS), which results in a continuum of disarray that is collectively called
fetal alcohol spectrum disorder (FASD). Many rodent models have been developed to understand
the mechanisms of and to reproduce the human FASD phenotypes. These animal FASD studies
have provided several molecular pathways that are likely responsible for the neurobehavioral
abnormalities that are associated with prenatal alcohol exposure of the developing CNS. Recently,
many laboratories have identified several immediate, as well as long-lasting, epigenetic modifications
of DNA methylation, DNA-associated histone proteins and microRNA (miRNA) biogenesis by using
a variety of epigenetic approaches in rodent FASD models. Because DNA methylation patterns,
DNA-associated histone protein modifications and miRNA-regulated gene expression are crucial
for synaptic plasticity and learning and memory, they can therefore offer an answer to many of
the neurobehavioral abnormalities that are found in FASD. In this review, we briefly discuss the
current literature of DNA methylation, DNA-associated histone proteins modification and miRNA
and review recent developments concerning epigenetic changes in FASD.
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1. Introduction
A change of gene expression evoked by mechanisms other than alterations in DNA sequence
contributes to the advancement of cell and tissue development and significantly aids in the
maintenance of a regular cell-specific function. Thus, dynamically regulated, epigenetic mechanisms
differing throughout life and between various cell populations have been shown to contribute to the
development of neuronal circuits and brain function. The major epigenetic alterations that are known
to regulate gene expression in the brain are as follows: (1) DNA methylation of cytosine residues
in promoter-rich cytosine phosphate guanine (CpG) islands; (2) acetylation, methylation and other
covalent posttranslational modification (PMT) of DNA-associated histone proteins; (3) chromatin
remodeling proteins that indirectly affect gene transcription; (4) pre-mRNA editing and splicing
by non-coding, small nucleolar RNA (snoRNAs); (5) mRNA processing, translation, and stability
of binding proteins, long non-coding RNAs (lncRNAs) and microRNAs (miRNAs); and (6) mRNA
translation that is controlled by cellular signaling molecules. These epigenetic mechanisms can
selectively respond to environmental factors and alter transcriptional machinery leading to altered
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physiological and pathological processes in the brain. An increasing number of environmental factors,
such as maternal care, stress, chemical agents, drugs of abuse, alcohol and nutritional disparity [1–8],
are undoubtedly shown to remodel epigenetics. However, the mechanism by which epigenetic
remodeling events are linked to environmentally induced diseases is poorly understood. The review
will provide a current understanding of epigenetic mechanisms and how alcohol exposure during
development, as a type of environmental teratogen, can influence epigenetic programs to alter gene
transcription and induce persistent early alcohol-associated abnormalities.
2. Epigenetic Mechanisms
2.1. DNA Methylation
Our modern understanding of epigenetic marks on DNA has provided insight into an additional
regulatory system in the cell that operates to regulate when and where a particular gene should
be expressed during development and normal cellular homeostasis. Historically, the presence
of methylated DNA was identified in mammals as soon as DNA was recognized as the primary
genetic material [9,10]. It was in 1948 when the presence of modified cytosine in the calf thymus
and the existence of this modified cytosine naturally in DNA was established [11]. Later, studies
have confirmed that methylation of cytosine (DNA methylation) regulate gene activity during
development [12,13]. Currently, DNA methylation along with other remodeling factors is considered
to be the major epigenetic remodeling event known to control gene activities (for references see [14,15]).
The methylation of cytosine (mC) is a covalent modification of DNA (Figure 1). A family of
DNA methyltransferases (DNMTs) transfer a methyl group from S-adenyl methionine (SAM) to the
cytosine residue to form 5-mC [16,17]. DNMT3a and -3b are characterized as de novo DNMTs partly
because they can establish a new methylation pattern for unmodified DNA. Conversely, DNMT1
copies the DNA methylation pattern from the parental DNA strand onto the newly produced daughter
DNA strand during DNA replication [18]. These unique functions of DNMTs supposedly ensure
that the DNA methylation pattern is maintained and preserved in a tissue-specific manner across
different individuals [19,20]. All three DNMTs are expressed extensively during embryo development,
and a significant level is found in postmitotic neurons in the mature mammalian brain [21–25].
These observations suggest that DNMTs and DNA methylation patterns have an important novel
role not only in early development but also in mature brain function [26,27]. Additionally, several
recent studies have described at least two mechanisms that actively remove mC. One mechanism is
through the activity of deaminases that catalyze the conversion of mC to thymidine [28]. A second
mechanism is through the action of ten-eleven translocation (TET) proteins (α-ketoglutarate-dependent
dioxygenases). TET proteins oxidize 5-mC to 5-hydroxymethylcytosine (5-hmC) using an oxygen-
and α-ketoglutarate-dependent mechanism. This is then oxidized to 5-formylcytosine and finally
to 5-carboxylcytosine (5-caC), which is then followed by the removal of the modified base through
base excision repair and glycosylase activity [15,28]. DNA demethylation processes via 5-hmC were
shown to operate in both developmental, as well as in an age-dependent manner in the mammalian
brain [29], thereby providing the basis for an important epigenetic regulator of gene expression [30].
These discoveries suggest that external factors, such as environmental exposure/experiences, have
the ability to modify the DNA methylation pattern. Indeed, research over the last decade suggests
that DNA methylation responds to environmental exposure/experience, thereby resulting in stable
phenotypes [31–33]. It has been suggested that these additional changes in DNA methylation that are
due to environmental influences may then be inherited in a transgenerational manner [34,35]. The vast
majority of recent data suggest that rapid and dynamic methylation and demethylation of specific genes
in the brain have a direct role in synaptic plasticity, learning and memory formation [14,15,26,36–40].
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Figure 1. Graphic representation of DNA methylation and its regulation by enzymatic mechanisms. 
Methylation of DNA begins with the covalent addition of a methyl group from s-adenyl methionine 
(SAM) [41] to the fifth carbon of the cytosine pyrimidine ring to form 5-methylcytosine (5-mC), a 
process that is catalyzed by a family of DNA methyltransferases (DNMTs). The majority of DNA 
methylation usually occurs at genes on cytosines that precede a guanine nucleotide or CpG islands. 
De novo methyltransferases (e.g., DNMT3a/b) transfer methyl groups to naked DNA CpG pairs (e.g., 
CpG/GpC to mCpG/GpC) [42,43]. DNMT1 is the maintenance methyltransferase that transfers 
methyl groups to hemimethylated DNA strands (e.g., mCpG/GpC to mCpG/GpCm) and maintains 
the parental DNA methylation pattern during replication [44]. 5-mC undergoes sequential oxidation 
to 5-caC by TET1 activities. 5-caC, through base-excision-repair (BER) mechanisms, results in the 
regeneration of cytosine [39,45,46]. 5-methylcytosine (5-mC); 5-hydroxymethylcytosine (5-hmC); 
5-formylcytosine (5-fC); 5-carboxylcytosine (5-caC). 
Another group of proteins that work closely with methylated DNA to control gene 
transcription in the brain is the family of methyl-binding proteins. Methyl-binding proteins are 
persistently expressed in the adult brain and often act as gene repressors through binding to 
methylated cytosines [47,48]. The methyl-binding protein 2 (MeCP2) is expressed at high levels in 
the brain, specifically in neurons, but not in glia, and correlates with neuronal maturation [49,50]. 
The MeCP2 recognizes and binds to DNA that contains single 5-mC sites. Additionally, the binding 
of MeCP2 to DNA further recruits transcriptional corepressor complexes, such as Sin3a and histone 
deacetylases (HDACs) 1 and 2 [47]. During neuronal activity, the activity of MeCP2 often results in 
the release of promoters due to the removal of the methylation mark on the DNA [51]. 
Posttranslational modifications of MeCP2, such as its phosphorylation, affect its ability to bind to 
DNA and alter gene expression [52,53]. Inhibition of MeCP2 phosphorylation is associated with 
improved synapse formation, synaptic plasticity and learning and memory behavior [54,55]. This is 
partly because activity-dependent phosphorylation may release MeCP2 from promoters, thereby 
making the gene sequence available for demethylation process. Furthermore, approximately 95% of 
cases of neurodevelopmental disorders, such as Rett Syndrome, are due to MeCP2 mutations [56,57]. 
In an animal model, a 50% increase in MeCP2 in the brain induces impairments in motor 
coordination, anxiety, long-term potentiation (LTP), learning and memory [58]. Therefore, DNA 
methylation followed by the binding of MeCP2 appears to have a critical role in synaptic plasticity 
and cognitive function. 
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Methylation of DNA begins with the covalent a iti f thyl group from s-adenyl methio ine
(SAM) [41] to the fifth carbon of the cytosine pyrimid ne r g to form 5-methylcytosine (5-mC), a process
that is catalyzed by a family of DNA methyltransf rases (DNMTs). The majority of DNA methylation
usually occurs at genes on cytosines that prec de guanine nucleotide or CpG islands. De novo
methyltransf rases (e.g., DNMT3a/b) transfer methyl groups to naked DNA CpG pairs (e.g., CpG/GpC
to mCp /GpC) [42,43]. DNMT1 is the maintenanc ethyltr sferase that transfers methyl groups
to hemimethylated DNA strands (e.g., mCpG/GpC to mCpG/GpC ) and maintai s the parental
DNA methylation pattern during replication [44]. 5-mC undergoes sequential oxidation to 5-caC by
TET1 activities. 5-caC, through base-excision-repair (BER) mechanisms, results in the regeneration
of cytosine [39,45,46]. 5-methylcytosine (5-mC); 5-hydroxymethylcytosine (5-hmC); 5-formylcytosine
(5-fC); 5-carboxylcytosine (5-caC).
Another group of proteins that work closely with methylated DNA to control gene transcription in
the brain is the family of methyl-binding proteins. Methyl-binding proteins are persistently expressed
in the adult brain and often act as gene repressors through binding to methylated cytosines [47,48].
The methyl-binding protein 2 (MeCP2) is expressed at high levels in t e brain, specifically in neurons,
but not in glia, and correl tes with neuronal maturation [49,50]. The M CP2 rec gnizes and binds to
DNA that contains single 5-mC sites. Additio ly, the binding of M CP2 to DNA further recruits
transcriptional corepre sor complexes, such as Sin3 and histone deace lases (HDACs) 1 and 2 [47].
During n uronal activity, the activity of M CP2 often results in the release of promoters due to the
rem val of the methylation mark on the DNA [51]. Posttranslational modifications of MeCP2, such
as its phosphorylation, affect its ability to bind to DNA and alter gene expression [52,53]. Inhibition
of MeCP2 phosphorylation is associated with improved synapse formation, synaptic plasticity and
learning and memory behavior [54,55]. This is partly because activity-dependent phosphorylation
may release MeCP2 from promoters, thereby making the gene sequence available for demethylation
process. Furthermore, approximately 95% of cases of neurodevelopmental disorders, such as Rett
Syndrome, are due to MeCP2 mutations [56,57]. In an animal model, a 50% increase in MeCP2 in
the brain induces impairments in motor coordination, anxiety, long-term potentiation (LTP), learning
and memory [58]. Therefore, DNA methylation followed by the binding of MeCP2 appears to have
a critical role in synaptic plasticity and cognitive function.
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2.2. Post-Translational Modification of DNA-Associated Histone Proteins
Nuclear DNA does not appear in free straight strands. It is highly condensed and wrapped
around nuclear proteins in the form of chromatin to accommodate chromosomes in the nuclei [59].
The chromatin consists of the nucleosomes. Each nucleosome core consists of two copies of
each H2A, H2B, H3 and H4 proteins as well as 147 base pairs of superhelical DNA wrapped
around this octamer [60,61]. These four histone proteins form a central structured globular domain
that closely contact with the DNA and a less well-structured amino-terminal tail domain [62,63].
Specific amino acid residues of the N-terminal tail domain of these histone proteins undergo
chemical modification through PTMs, including acetylation, methylation, phosphorylation, and
sumoylation [64]. This distinctive chemical posttranslational modification influences the overall
chromatin structure and recruitment of DNA binding proteins and allows for the loosening or
tightening of the chromatin around particular genetic loci, thereby resulting in the activation or
repression of specific gene expression [64]. As these PTM can alter gene expression without changing
the DNA sequence, they have frequently been termed “epigenetic” modifications, although many
changes are not maintained across the cell cycle [65].
2.2.1. Histone Acetylation and Deacetylation
Histone acetyltransferases (HATs) transfer the acetyl group from acetyl-coA to the ε-amino
group of lysine residues of histone proteins (Figure 2). Three main families of HATs, general control
nonderepressible-5 (Gcn5), MYST, and p300/cAMP response element-binding protein (CREB) binding
protein (CBP), share a conserved acetyl-coA binding site and often work in large multi-protein
complexes [66,67]. The acetylation of histone proteins affects histone-histone protein interactions
between neighboring nucleosomes and also interactions between histones and transcription factors
(for references see [67]). These alterations can influence the individual nucleosome structure as well
as the higher-order chromatin structure, thereby causing a more open and permissive chromatin
environment for transcription. While HATs are often not specific to individual lysine amino acid
residues, they fulfill specific functions. The broad catalytic role of HATs means that its localization
to the proper genomic loci is essential for its particular function. The non-catalytic domains of
HATs direct the protein to the appropriate location [68]. Acetylated histones provide a more relaxed
chromatin conformation due to hydrophobicity and reduced electrostatic interactions. Additionally,
acetylated histones further recruit bromodomain-containing proteins, which are primarily transcription
factors and cofactors, and facilitate gene expression [69]. Among the HATs, CBP/p300 is critically
involved in development. Genetic mutations and deletions of either enzyme cause Rubinstein-Taybi
syndrome, which is characterized by intellectual disabilities, among other impairments [70]. The
elevated expression of p300 mRNA was found in neural tissue and the genetic deletion of CBP or p300
resulted in an open neural tube through the impairment of paired box 3 (PAX3) and the activation of
enhancer binding protein 2 (AP2) expression, thereby delaying embryo development [71,72]. Both
Gcn5/Myc HATs co-regulate transcriptional programs in neural stem cells (NSCs) that are required
for stem cell proliferation and brain development [73]. A number of memory tasks have been shown
to enhance specific histone H3 and H4 acetylation immediately after memory performance through
the enhanced expression and activity of several HATs (Taf1/Kat4, Gcn5/Kat2a, PCAF, Tip60, p300
and CBP) in rodents (for references see [74–77]). Recently, specific activators of HATs (SPV106,
CSP-TTK21, etc.) [78,79] have been developed and used in certain neurological disorders for their
beneficial function in augmenting neurodegeneration and cognitive function (for references see [80–82]).
Thus, well-characterized HAT activators may be useful in treating cognitive dysfunction found in
FASD children.
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Figure 2. Schematic representation of DNA-associated histone protein acetylation and deacetylation 
by histone acetyltransferase (HAT) and histone deacetylase (HDAC) enzyme families. The net 
acetylation at lysine residues of histone proteins of nucleosomes is decided by the interplay between 
acetylation and deacetylation processes through HAT and HDAC enzyme activities, respectively. 
The box provides different families and classes of HAT and HDAC enzymes. CBP, cyclic 
adenomonophosphate response element-binding (CREB) binding protein; GNAT, Gcn5-related 
N-acetyltransferases; hGCN5, human general control of amino acid synthesis protein 5-like 2; PCAF, 
p300/CBP-associated factor; ELP3, elongation protein 3; TIP60, TAT interacting proteins 60; TFIIIC90, 
transcription factor IIIC 90kDa; TAF1, TATA Box Binding Protein-Associated Factor; SRC1, steroid 
receptor coactivator 1; ACTR, activator of thyroid receptor; p160, receptor coactivators proteins 160; 
CLOCK, Clock Circadian Regulator. 
Histone lysine deacetylases (HDACs) are a family of chromatin remodeling enzymes that 
remove acetyl groups from proteins and restrict the access of transcription factors to the DNA, 
thereby inhibiting gene expression (Figure 2). There are 11 well-described HDACs that are grouped 
into the following four classes, based upon their sequence, subcellular distribution and function: 
Class I (HDAC1, 2, 3, and 8), Class IIa (HDAC4, 5, 7, 9), Class IIb (HDAC6, 10), and Class IV HDACs 
(HDAC11) [83]. These HDACs are zinc-dependent enzymes. Class I HDACs (1 to 3 and 8) are largely 
localized to the nucleus, but they can also be found in the cytoplasm. Class II HDACs (4 to 7, 9, and 
10) and IV HDAC (11) are either found as nucleocytoplasmic shuttling enzymes or primarily 
cytoplasmic. Class IIa HDACs (4, 5, 7, and 9) have been shown to exhibit low intrinsic deacetylase 
activity [84]. A separate family of HDACs, which are referred to as sirtuins, are classified as Class III 
HDACs. These are nicotinamide adenine dinucleotide (NAD)-dependent enzymes, which have 
mechanisms of action that are distinct from those of other HDACs [85,86]. Not much is presently 
known about HDAC11, as more studies have yet to emerge about its role in the adult brain. Class I 
HDACs were expressed at more elevated levels throughout the adult brain in comparison with 
many other HDACs [87–89]. The precise localization and cell-specific expression of individual 
HDACs in the brain suggests that each HDAC may have a broader, yet specific, significant role in 
Figure 2. Schematic representation of DNA-associated histone protein acetylation and deacetylation by
histone acetyltransferase (HAT) and histone deacetylase (HDAC) enzyme families. The net acetylation
at lysine residues of histone proteins of nucleosomes is decided by the interplay between acetylation
and deacetylation processes through HAT and HDAC enzyme activities, respectively. The box provides
different families and classes of HAT and HDAC enzymes. CBP, cyclic adenomonophosphate response
element-binding (CREB) binding protein; GNAT, Gcn5-related N-acetyltransferases; hGCN5, human
general control of amino acid synthesis protein 5-like 2; PCAF, p300/CBP-associated factor; ELP3,
elongation protein 3; TIP60, TAT interacting proteins 60; TFIIIC90, transcription factor IIIC 90kDa; TAF1,
TATA Box Binding Protein-Associated Factor; SRC1, steroid receptor coactivator 1; ACTR, activator of
thyroid receptor; p160, receptor coactivators proteins 160; CLOCK, Clock Circadian Regulator.
Histone lysine deacetylases (HDACs) are a family of chromatin remodeling enzymes that remove
acetyl groups from proteins and restrict the access of transcription factors to the DNA, thereby
inhibiting gene expression (Figure 2). There are 11 well-described HDACs that are grouped into
the following four classes, based upon their sequence, subcellular distribution and function: Class I
(HDAC1, 2, 3, and 8), Class IIa (HDAC4, 5, 7, 9), Class IIb (HDAC6, 10), and Class IV HDACs
(HDAC11) [83]. These HDACs are zinc-dependent enzymes. Class I HDACs (1 to 3 and 8) are largely
localized to the nucleus, but they can also be found in the cytoplasm. Class II HDACs (4 to 7, 9, and 10)
and IV HDAC (11) are either found as nucleocytoplasmic shuttling enzymes or primarily cytoplasmic.
Class IIa HDACs (4, 5, 7, and 9) have been shown to exhibit low intrinsic deacetylase activity [84].
A separate family of HDACs, which are referred to as sirtuins, are classified as Class III HDACs. These
are nicotinamide adenine dinucleotide (NAD)-dependent enzymes, which have mechanisms of action
that are distinct from those of other HDACs [85,86]. Not much is presently known about HDAC11, as
more studies have yet to emerge about its role in the adult brain. Class I HDACs were expressed at more
elevated levels throughout the adult brain in comparison with many other HDACs [87–89]. The precise
localization and cell-specific expression of individual HDACs in the brain suggests that each HDAC
may have a broader, yet specific, significant role in neuronal development and function. Indeed,
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studies of a conditional knockout of both HDAC1 and HDAC2 suggest that neuronal progenitors
fail to differentiate into mature neurons and lead to cell death, thereby resulting in animal death by
Postnatal Day 7 (P7) [90]. Additionally, HDAC2 was also critically required to suppress progenitor
transcripts during neuronal differentiation of adult-generated neurons [91]. Furthermore, HDAC
1/2 support the stability of synaptic networks during early brain development by suppressing the
maturation of excitatory synapses [92]. The genetic deletion of HDAC3 suppresses the translocation of
thyroid hormone receptors (SMRT) that regulate the neurogenic pathway to the nucleus [93]. The class
II HDAC5 has also been suggested to have an important role in neuronal differentiation [94]. HDAC10
has also been shown to interact with and maintain a deacetylated state of Pax3, a key transcription
factor in stem cell maintenance and neurogenesis [95]. Together, these findings suggest that HDAC
family members control gene expression and cell fate during brain development into adulthood.
Some HDAC families function independently of their catalytic activity function in neurite formation,
dendrite and axonal growth (for references see [96]). Methods that involve pharmacological (HDAC
inhibitors) and genetic manipulations of HDACs have shown a role of an individual family of HDACs
in learning and memory process (for references see [92]). The conditional, brain-specific genetic
deletion of HDAC2 in the mouse brain display enhanced acquisition of associative fear learning,
whereas the overexpression of HDAC2, but not HDAC1, in the brain led to deficits in fear learning and
aversively motivated spatial memory performance in the Morris water maze task [97]. Administration
of an HDAC inhibitor, in addition to improving learning and memory, also enhanced the induction
and maintenance of LTP at hippocampal and amygdala synapses, two brain regions that are essential
for associative learning [76,98–100]. It should be noted that many learning and memory studies have
utilized trichostatin (TSA) or suberoylanilide hydroxamic acid (SAHA) as an HDAC inhibitor. In doing
so, researchers have observed that they appear to exhibit specificity, as these drugs act on class I, but
not class II, HDACs [101]. The preclinical use of HDAC inhibitors as therapeutic agents was effective
in many animal models of neurological disorders and the study of the benefits of HDAC inhibition for
treating several cognitive disorders is underway [102]. Therefore, well-characterized HDAC inhibitors
may be valuable for the improvement of the cognitive function of FASD children.
2.2.2. Histone Methylation and Demethylation
The methylation of histones usually occurs at the arginine or lysine N-terminal region of histones,
which causes multiple effects, including the activation or inhibition of gene transcription. Each
arginine residue in histone proteins can be subjected to monomethylation and symmetric/asymmetric
dimethylation. Similarly, each lysine residue can be monomethylated, dimethylated and trimethylated
and also adjacent residues can form different methylation combinations [103–106]. Arginine residue
methylation is catalyzed by the family of arginine methyltransferases (PRMT). PRMT1 catalyzes
the monomethylation and asymmetric dimethylation of arginine residues, thereby resulting in gene
activation. PRMT2 catalyzes monomethylation and symmetric dimethylation of arginine residues,
which results in gene suppression. Furthermore, the cofactor-associated arginine methyltransferase
(CARM1) catalyzes the formation of monomethylation and asymmetric dimethylation of arginine
residues, which promotes gene expression.
Histone methyltransferases (HMTs) that methylate not only lysine amino acids of histone proteins
but also other proteins, are called lysine methyltransferases (KMTs) [107] for their broad enzymatic
activity and substrate specificity (Figure 3A). All KMTs, except for KMT4, contain a conserved Su
(var)3-9, Enhancer of Zeste, Trithorax (SET) domain that exhibits catalytic activity (for references
see [108]). The presence of a characteristic homologous sequence [107,109] has helped to classify KMTs
into distinct subcategories. Lysine methylation of histone H3K4 is catalyzed by a family (KMT2)
of mixed lineage leukemia (MLL) proteins, such as SET1A, SET1B, MLL1, MLL2, MLL3, MLL4
and ASH1 [110–112]. H3K4 methylation closely correlates with the activation of gene expression.
H3K9 methylation is catalyzed by a group of methyltransferases (KMT1: SUV39H1, SUV39H2,
Eu-HMTase/GLP, G9A and ESET/SETDB1; KMT8:RIZ1), whose catalyzing substrates and resulting
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products are different. The trimethylation of H3K9 is catalyzed by SUV39 and results in the formation
of heterochromatin and transcriptional inhibition [113]. The dimethylation of H3K9 is catalyzed by G9a
and results in a euchromatin structure and the suppression of gene expression [6,114]. G9a-like protein
(GLP) can form a hetero polypeptide complex with G9a, and together they catalyze the formation of
H3K9 dimethylation [115]. ESET/SETDB1 catalyze the trimethylation of H3K9 enzymes [116], which
results in gene inhibition. H3K27 methylation is mediated by the EZH2 enzyme (KMT6) and results in
the inhibition of gene transcription and has been shown to have a significant role in fetal development
and cell differentiation [117,118]. H3K36 methylation activity is performed by (KMT3) SET2, SYMD2
and NSD1 enzymes and is associated with active transcription [119–121]. H3K4 methylation by
SYMD1-3 enzymes is related to gene activation [122]. H3K79 di- and tri-methylation are performed by
DOT1L enzymes (KMT4) and are universally associated with active transcription [123]. H4K20 mono-
or tri-methylation is catalyzed by SET8 and SUV420H1/2 enzymes (KMT5), respectively, and have
been linked with transcriptional repression [124].
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Figure 3. DNA-associated histone protein lysine methylation (A) and demethylation (B) by histone
methyltransferase (KMTs) and histone demethylase (KDMs) enzyme families. Histone H3 and H4 tails
with known lysine methyltransferases (KMT1-8) and demethylases (KDM1-7) are shown under each
specific lysine residue.
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Experimental data concerning enzymatic histone demethylation were not known until the
discovery of the lysine-specific demethylase 1 (LSD1) (KDM1 family). LSD1 (KDM1A) is characterized
as a component of the v-raf murine sarcoma viral oncogene homolog B1 (BRAF)-histone deacetylase
(HDAC) (or BHC) complex that contains the restrictive silencer factor (REST) co-repressor, CoREST.
CoREST has been shown to function as a repressor of neuronal genes in non-neuronal cells [125–127].
LSD1, through its amine oxidase domain, has been shown to act as a transcriptional repressor and to
demethylate K3K4, thereby providing the first evidence that histone methylation is a dynamic and
reversible event [128]. LSD2 (KDM1B) was recently described as an additional H3K4 demethylase [129].
Similar to KDM1A, KDM1B was shown to demethylate the mono- and di-methylated histone
H3K9 [130]. Soon after discovery of the KDM1 family, a protein containing a Fe2+ dioxygenase
Jumonji-C (JmjC) domain (KDM2 family proteins) was characterized as a specific H3K36me1/2
demethylase (KDM2A and B), which does not demethylate H3K36me3 [131]. Now, accumulating
evidence suggests the presence of specific demethylases for all of the major methylated histones
that have so far been studied (Figure 3B), with the exception of methylated histone H3K79, despite
its characterization as a reversible process [123]. The KDM3 family of proteins was characterized
as the second family of JmjC histone demethylases (KDM3A/JHDM2A and KDM3B/JHDM2B)
and was shown to demethylate mono- and di-methylated H3K9, thereby resulting in active gene
expression [132]. The KDM4 family proteins consist four histone demethylases (KDM4A–4D or
JMJD2A–2D, respectively). All KDM4 demethylases remove di- and tri-methylation from histone
H3K9 and H3K36 proteins [133–135]. In addition to the JmjC domain, they all contain a conserved JmjN
domain. All, except KDM4D, have tandem plant homeodomain (PHD) fingers and Tudor domains
that help to recognize specific histone methylation marks [136,137]. These families of proteins were
activated in response to hormonal activity. For example, KDM4A and KDM4D act as androgen receptor
(AR) coactivators: estrogen receptor (ER) activation results in KDM4B-mediated demethylation
of H3K9me3 proteins [138,139]. KDM5 (KDM5A–5D/JARID1A–1D) specifically catalyzed the
demethylation of histone H3K4me2/3 proteins [140–144]. These proteins are characterized as
multi domain-containing proteins and include a combination of JmjC/JmjN catalytic domains, with
an AT-rich interaction domain (ARID) DNA-binding domain, a C5HC2 zinc finger and two to three
PHD fingers. The PHD finger domains of KDM5A and KDM5C were shown to facilitate binding to
methylated H3K4 or H3K9, respectively [141,145]. KDM6 family proteins contain KDM6A/UTX and
KDM6B/JMJD3 demethylases. These enzymes catalyze the removal of di- and tri-methyl groups form
histone H3K27me2/3 proteins [146–150] and result in transcriptional activation. KDM6A functions
in development via its association with the KMT2/MLL proteins to regulate H3K4 methylation
followed by HOX gene expression [149]. The KDM7 (PHF2) family enzymes contain three members
(KDM7A/JHDM1D, KDM7B/PHF8, and KDM7C/PHF2). This enzyme family removes mono and
di methyl group from histone H3K91/2 and H3K27me1/2 proteins [139,151–157]. Additionally, they
regulate the expression of genes involved in X-linked mental retardation and expression of ribosomal
RNA [154,155,157]. Additionally, PHF8 demethylates histone H4K20me1 proteins [155,157,158]. KDM7
family proteins have a PHD finger domain that helps to recognize and bind to histone the H3K4me3
mark. This ensures substrate specificity, genomic occupancy, and the regulation of target gene
expression by KDM7 demethylases [152,156,159–161]. Few studies have explored the participation of
histone demethylase in developmental alcohol studies, except in one study in which acute prenatal
alcohol exposure at GD7 was shown to disrupt the transcripts that encoded KDM1A and KDM4A
proteins [162] (see Section 3 for details).
2.3. MicroRNAs
MicroRNAs (miRNAs) are a family of small, non-coding RNA molecules that facilitate the
degradation of untranslated regions of target mRNAs. Thus, miRNAs play a critical epigenetic
function by inhibiting the translation and transcription of a network of genes encoding for proteins.
MicroRNAs are generated from longer precursor miRNA (pre-miRNAs) in sequential biogenesis
Brain Sci. 2016, 6, 12 9 of 32
pathways (Figure 4). MicroRNA genes primarily bind to the imperfect complementary sequence
that forms a secondary stem-loop structure within the pre-miRNAs. This structure, along with its
guide strand [163,164], act as a substrate for two double-stranded RNases, Drosha (nucleus) and
Dicer (cytoplasmic) [165]. This specific targeting occurs through a partial complementary association
between the mRNA’s 31UTR and 51 end of the microRNA (a 6–8 nucleotides sequence long) regions.
This partial association facilitates the targeting of a single miRNA to many mRNAs at the same time
and vice versa. This provides a mechanism wherein a single mRNA can be influenced by diverse
miRNAs [166,167]. To date, a few miRNAs have been shown to be expressed in mammalian brains and
recent estimates suggest the presence of 1100 or more human miRNAs, which regulate the expression
of nearly two-thirds of all genes [168]. Thus, they can control the expression of networks of genes and
whole pathways and therefore are considered as master regulators of gene expression [169]. Therefore,
miRNAs are critically essential for the proper development and functioning of the adult brain. Indeed,
many recent studies suggest the involvement of several miRNAs in an array of cellular homeostatic
processes, including developmental timing, cellular differentiation, neural patterning, apoptosis and
synaptic plasticity [170–173].
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Figure 4. The schematic diagram of iRNA biogenesis and function. In the nucleus, RNA polymerase
II (Pol II)-dependent transcription of a miRNA-encoding gene, which may include both intron- and
exon-coding regions, results in the formation of a long primary miRNA transcript (pri-miRNA) that is
50-capped and 30-polyadenylated. This pri-miRNA transcript is subject to nuclear processing by the
microprocessor complex, which includes DCGR8 and Drosha, into the precursor miRNA (pre-miRNA)
transcript. Pre-miRNAs are transported out of the nucleus to the cytoplasm by Exp5 and Ran-GTP.
Pre-miRNA can then be further cleaved by Dicer/TARBP to generate a mature miRNA. The mature
miRNA is incorporated into the RNA-induced silencing complex (RISC), which will select mRNA
transcripts for the down-regulation of protein expression. In the synapses, miRNA can regulate the
local down-regulation of protein expression. Certain conditions, such as neuronal activity, could affect
the signaling events as well as miRNA formation. Additionally, genes regulated by miRNA can act on
synaptic activity-dependent signaling pathways that promote the activation of epigenetic factors (e.g.,
CREB and MeCP2), which in turn can control miRNA transcription in the nucleus.
Brain Sci. 2016, 6, 12 10 of 32
Studies involving individual genetic deletion of miRNA have suggested that miR-124, miR-125b,
miR-132, miR-134, miR-137, and miR-138 in neurons regulate synaptic development and dendritic
branching (for references see [174]). The disruption of miRNA biogenesis pathways, such as Dicer,
which affects the expression of all miRNAs, can induce impaired cell differentiation, reduction in
neuronal size, loss of dendritic branching, disturbed axonal guidance [175], impairments in inhibitory
synaptic transmission and cognitive dysfunction [176]. It should be noted that the activity-dependent
regulation of gene expression is essential for synaptic plasticity and memory formation and similar
neuronal activity was shown to regulate miR-132 expression in a CREB signaling pathway-dependent
manner [177,178]. In a recent study, reduced miR-125a levels were found in synaptoneurosomes after
activation of mGluR1/ 5 receptors, thereby indicating that neuronal activity may influence the miRNA
turnover [179]. Additionally, miRNAs in neurons decay much faster than in non-neuronal cells, and
their turnover rate is activity-dependent [180]. Therefore, similar to many learning and memory
genes, miRNAs can be regulated in a neuronal activity-dependent manner. It has been suggested that
neuronal activity is one mechanism for the high turnover rate of miRNAs in neurons. Consistent with
their neuronal function, increasing evidence suggests that the activity of miRNAs is directly implicated
in the pathogenesis of complex neuropsychiatric disorders (for references see [181]) that are linked
to abnormalities in synaptic plasticity as well as in neurodegenerative diseases [182,183]. Limited
studies have explored miRNA dysregulation in FASD animal models, as described later in this section.
Therefore, an understanding of the signaling mechanisms that regulate the patterns and activity of
miRNA expression have the potential to serve as potential targets for FASD treatment.
3. Alcohol’s Influence on Epigenetic Mechanisms in the Developing Brain
The presence of fetal alcohol syndrome was recognized after the initial study [184] suggesting
series of deformities in the offspring of alcoholic mothers. Among the several possible consequences of
developmental alcohol exposure, defects in brain maturation and the considerable lifelong behavioral
impairments have been the most catastrophic. The most serious consequences of early developmental
alcohol exposure are fetal alcohol syndrome (FAS) [184], which is characterized by pre- and post-natal
growth defects, craniofacial anomalies and persistent impairments of CNS function. FAS occur in 1–2
of every 1000 newborns. It has been acknowledged as an important cause of non-genetic intellectual
disabilities and behavioral impairments in the world [185–189]. Nevertheless, now, it has become
clear that FAS is not the only enduring defect that results from developmental alcohol exposure.
Unquestionably, the term fetal alcohol spectrum disorders (FASD) [190] (estimated the prevalence of
as high as 2%–5%) has been used to represent the persistent nature of developmental alcohol effects,
with FAS on the stronger side of the spectrum. Though the behavioral profile of FASD is somewhat
limited [191], the available literature suggests that FASD is associated with many neuropsychological
impairments, such as verbal learning/recall abilities, learning and memory [187,192–196]. These
neuropsychological deficits create many daily challenges for individuals with FASD and are also
responsible for causing a majority of intellectual disability in the Western world [194,196–198].
The neurobehavioral outcome of FASD is also dependent on the amount [199,200], pattern (continuous
vs. binge drinking) and developmental timing [201] of alcohol exposure. Additionally, the pattern
of alcohol exposure can often undermine alcohol dose effects. For example, binge-like exposures
result in more severe behavioral outcomes than does chronic exposure [202,203]. Furthermore, several
other factors, such as maternal metabolism, genetic susceptibility, and variation in the vulnerability of
different brain regions, may contribute to behavioral outcomes. Nonetheless, factors that alter the peak
blood alcohol levels (BALs) experienced by the embryo or the fetus (e.g., maternal metabolism) are
expected to affect the occurrence and severity of FASD. Unfortunately, this information is often hard to
obtain, mainly in retrospectively recruited samples, and individual studies provide varying degrees of
detail concerning the amount and patterns of exposure. These issues highlight the modifying variables
that contribute to the vast range of phenotypes presented in FASD children.
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Persistent data from all areas of biological science, such as epidemiology, genetics, epigenetics,
neuroscience and neuroimaging studies, strongly suggest that many adult neuropsychiatric illnesses
have a neurodevelopmental origin [204]. Recent technological advances and experimental evidence
have provided more precise mechanistic insights on the developmental origin of adult diseases.
Disturbance of brain development at sensitive and critical periods by adverse environmental exposure,
along with genetic programming, results in the early or late manifestation of heterogeneous clinical
conditions [205–209]. The range of developmental deficits varies from learning or cognitive functions
to global impairments of social skills or intellect. To date, the etiological basis of the majority of
developmentally related adult diseases, such as autism spectral disorder (ASD), attention deficit
hyperactivity disorder (ADHD) and FASD conditions, are still unknown. Data from several studies
support their polygenic and multifactorial, including epigenetic etiology [4,6,210–213].
Using animal models of FASD, several studies have reported epigenetics changes, including DNA
methylation [214–219], DNA-associated histone modification [4–6,213,220–224] and miRNAs [225–231].
Acute alcohol exposure at Gestational Days (GD) 9 through 11 was found to induce hypomethylation
of DNA in the fetus [215], and this study was the first one to indicate that DNA methylation may
contribute to abnormalities found in FAS. In the prenatal alcohol model, alcohol was shown to
significantly decrease astroglial-specific marker, glial fibrillary acidic protein (GFAP) immunoreactivity
and its mRNA levels in both astrocytes in primary culture and brains of pups from alcohol-fed mothers.
The reduced GFAP transcript found in fetal brains was due to the hypermethylated state of the
GFAP DNA [232]. These findings suggest that alcohol-induced DNA hypermethylation, followed by
impaired GFAP expression and astroglial development, may underlie the deficits in brain functions
that are observed after prenatal alcohol exposure. In some instances, male alcohol exposure before
breeding resulted in reduced cytosine methyltransferase mRNA levels in paternal sperm, thereby
suggesting that distorted genomic imprinting caused by DNA hypomethylation leads to the expression
of normally silent paternal alleles [233]. This phenomenon was also demonstrated between alcohol
use in men and hypomethylation of paternally imprinted loci in sperm DNA in genomic regions that
are essential for embryonic development, therefore providing a mechanism for paternal effects in the
etiology of FASD [218].
The imprinted genes are expressed mainly from either the paternal or maternal allele and are
important regulators of fetal growth and development [234]. Additionally, imprinted genes have
been found to cause some birth defect syndromes in humans [235,236] and in animals [237–239].
In a whole-embryo culture, alcohol enhanced DNA methylation, particularly in genes on chromosome
7, 10 and X, and a neural tube defect phenotype. Enhanced DNA methylation was found in imprinted
genes, genes that are essential for cell cycle, growth, apoptosis, cancer, and in a significant number of
genes important for olfaction, and with associated changes in gene expression [217]. In monolayer
cultures of NSCs, alcohol was shown to increase DNA methylation of multiple cell cycle genes and
increased the expression and activity of DNA methyltransferases [240]. In another study, prenatal
alcohol-exposed embryos exhibited decreased DNA methylation at insulin-like growth factor 2
(IGF2) transcripts, which was reversed by methyl supplementation [214]. In NSC culture, alcohol
exposure retarded the migration, neuronal formation, and growth processes of NSCs. Additionally,
alcohol exposure prevented DNA methylation of specific genes related to neural development, eye
development and developmental disorders, thereby suggesting that developmental alcohol alters
DNA methylation of genes that are critical for regulating neural development [219]. Furthermore,
in studies using a whole-embryo culture, alcohol delayed the DNA methylation program, which
paralleled the developmental impediment of the neural tube in a spatial and temporal manner [241].
A delay in hippocampus development was also associated with altered 5-mC and 5-hmC in DG and
CA region of the hippocampus in prenatally alcohol-exposed embryos or P7 mice [242]. Although
these studies have demonstrated the presence of altered methylation program that correlated well
with a developmental delay in the formation of the neuronal tube and the hippocampus, whether the
abnormal DNA methylation is responsible for the developmental delay and behavioral deficits remains
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to be established in further studies. In another animal model of FASD (third-trimester equivalent
pregnancy), studies have suggested a direct link of this phenomenon. Alcohol administration in
Postnatal Days 2–10 (P2–10) mice significantly caused hypermethylation of DNA in the hippocampus
(HP) and prefrontal cortex (PFC) at P21. Administration of choline (P2–20), a nutrient supplement that
has been shown in a rat model to rescue some of the alcohol’s behavioral effects [243,244], prevented
DNA methylation in alcohol-treated P21 mice HP and PFC tissues [245]. In a gestational alcohol
model, alcohol increased the methylation of the proopiomelanocortin (Pomc) DNA in a gene- and
cell-specific manner in the adult rat hypothalamus despite the exposure to alcohol having ended during
the prenatal period [221]. Interestingly, the hypermethylated Pomc gene was found in the sperm
of prenatal alcohol-exposed F1 offspring that was transmitted through the F3 generation through
the male germline [221]. Global DNA methylation was found to be reduced by alcohol in an in vitro
murine embryonic fibroblast (MEF) model. Reduction in DNA methylation was associated with
alcohol-induced proteasomal-mediated degradation of DNA methyltransferases (DNMT-1, DNMT-3a,
and DNMT-3b) [246]. In a neonatal animal model of FASD (third-trimester equivalent pregnancy),
the administration of alcohol to P7 mice resulted in reduced global DNA methylation in neonatal
HP and neocortical (NC) tissues [23] and impaired learning and memory in adult animals [4,213,247].
This reduction in DNA methylation was linked with alcohol-induced caspase-3 mediated degradation
of DNMT-1, DNMT-3a proteins [23] and impaired learning and memory [4,213,247]. Combined
pre-(GD1-21) and postnatal (P2–10) alcohol exposure resulted in a significant increase in DNA
methyltransferase activity (DNMT), as well as Dnmt1 and Dnmt3a gene expression in the HP of
P21 rats [248]. These studies warrant future investigation to understand how these events affect
global or gene-specific DNA methylation and learning and memory. Prenatal alcohol exposure
decreased DNA methylation in the solute carrier family 17 member 6 (SLC17A6) promoter region,
which encodes vesicular glutamate transporter 2 (VGLUT2). In contrast to Slc17a6 mRNA levels, HP
VGLUT2 protein levels were significantly reduced in adult alcohol-exposed offspring and suggest
that DNA methylation-regulated glutamate neurotransmission in the hippocampus could contribute
to the cognitive and behavioral phenotypes that are observed in FASD [249]. Another important
observation was made using gestational alcohol exposure in epigenetically sensitive alleles (metastable
epialleles) in the Agouti viable yellow (Avy) mice model [250]. The activity of Avy is changeable among
genetically identical mice, thereby resulting in mice with a range of coat colors [from yellow to mottled
to agouti (termed pseudoagouti)] [251]. In this model, exposure to alcohol increases the probability of
transcriptional silencing of the Ayy locus through DNA methylation, thereby resulting in more mice
with an agouti-colored coat [35]. A genome-wide DNA methylome analysis revealed widespread
alcohol-induced alterations with significant hypermethylation of many differentiation-related genes
in human embryonic stem cells (hESCs) [252]. In a Japanese rice fish embryogenesis model, alcohol
was shown to have the capacity to specifically alter the developmental pattern of DNA methylation
machinery [253]. A genome-wide analysis of DNA methylation in adult mice exposed to prenatal
alcohol using voluntary alcohol exposure paradigm indicated that a large number of gene promoter
regions are differentially affected. Furthermore, network analysis of these promoter regions has
suggested that behavior-, neurological disease-, and psychological disorder-associated networks are the
most significantly affected ones [254]. Enrichment analysis using the genes that were up-methylated
in FASD children from 5 to 18 years of age showed a significant enrichment in genes associated
with neurodevelopment and diseases [255]. It is clear from the above-discussed studies that the
alteration of global DNA methylation or methylation (Table 1) of specific genes/promoter regions is
dependent upon several factors, including the specific gene or tissue, amount and pattern of alcohol
exposure, as well as the developmental timing of exposure. DNA methylation or demethylation
(5-hCm) can influence gene expression through enhancing or preventing the recruitment and binding
of transcriptional regulatory proteins with decreased [256] or increased [257,258] transcription activity.
Findings also suggest that increased DNA methylation in the gene body can lead to an increased
transcription, thus implicating a bidirectional regulation of transcription, depending upon the site of
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the DNA methylation mark [259]. The mechanisms of the interplay between DNA methylation and
transcription activity are therefore crucial. Furthermore, the signaling events that are responsible for
DNA methylation-related chromatin remodeling are largely unknown and warrant future research in
this line to develop potential therapeutic approaches to treat FASD.
Table 1. Summary of the developmental alcohol-induced DNA methylation modifications.
Alcohol Exposure Tissue Examined Effects
1. GD 9–11 GD 12 fetus Reduced DNA methylation [215]
2. GD Cultured astrocytes BDNF gene hypermethylation [260]
3. GD 1–18 PD 10 Hypermethylation of the GFAP gene [232]
4. Oryzias latipes embryos 2–6 dpf No change in Aldh1A2 gene promotermethylation [261]
5. Embryo (E8.25) cultures Embryo cultures Both hyper/hypomethylation of genepromoter [217]
6. Neural stem cells in culture NSCs culture Hypermethylation of cell cycle genes [240]
7. Neural stem cells in culture NSCs culture Hypomethylation of NSC genes [219]
8. GD 9 E-15 and 17 Decreased Igf2 gene DNA methylation [214]
9. PD 2–10 PD 21 Increased DNA methylation [245]
10. GD 1–22 PD 21 Enhanced DNMTs activity [248]
11. hESC Cell lines No change in gene methylation [262]
12. hESC Cell lines Hypermethylation of many regions ofchromosomes [252]
13. GD 1–17 Cultured neural progenitor cells Disrupt DNA methylation machinery anddelays the maturation of dentate gyrus [242]
14. Murine embryonic fibroblasts Fibroblasts Impaired DNA methylation and DNMT1,DNMT3a and DNMT3b proteins [246]
15. GD 7–21 PD 60–65 Increased DNMT1protein and Pomc genemethylation [220]
16. PD 7 PD 7 Reduced DNA methylation, DNMT1andDNMT3a proteins [23]
17. GD 0.5–8.5 PD 28 Decreased mRNA levels of Dnmt1 andDnmt3a genes [263]
18. GD 0.5–8.5 PD 28 Both up/down regulation of DNAmethylation [264]
19. GD 0.5–8.5 PD 87 Decreased Slc17a6 gene promoter [249]
20. Oryzias latipes embryos 2–6 dpf Altered DNMT1 mRNA [265]
dpf, day post fertilization; GD, gestational day; PD, postnatal day; NSCs, neuronal stem cells; GFAP, glial
fibrillary acidic protein; Aldh1A2, aldehyde dehydrogenase 1 family, member A2; Igf2, Insulin-Like Growth
Factor 2; DNMT, DNA methyltransferase; hESC, human embryonic stem cells; Pomc, Proopiomelanocortin;
Slc17a6, Solute Carrier Family 17 (Vesicular Glutamate Transporter), Member 6.
Limited laboratories using many animal models of FASD have demonstrated the participation of
DNA-associated histone proteins modifications in responses to alcohol exposure during the different
sensitive period of brain development. The earliest report suggests that binge-like alcohol exposure
reduces the level of histone H2A family proteins in endothelial caveolae cells [266]. Another study
demonstrated the reduced expression of the CREB binding protein (CBP), a histone acetyltransferase,
in the rat cerebellum exposed to alcohol during the third trimester-equivalent of human pregnancy.
These studies also demonstrated the global reduction of both acetylated histone H3 and H4 proteins
in the cerebellum [222]. In a prenatal alcohol model, alcohol was shown to affect the hypothalamus
function, such as stress axis responsiveness, which may be due to reduced expression of Pomc gene
and production of β-endorphin protein in the arcuate (ARC) nucleus of the hypothalamus. In the same
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arcuate nucleus, reduced staining of H3K4me2,3, acetylated H3K9 and increased H3K9me2 was also
observed in alcohol-exposed male offspring. Consistent with acetylated or methylated histone H3 and
H4 staining data, the transcriptional activity of enzymes responsible for methylation or acetylation of
histone H3 and H4 proteins (G9a, Set7/9, Setdb1 and HDAC2) were also altered in alcohol-exposed
offspring [221]. In another study, during the third-trimester equivalent human pregnancy animal
model, alcohol was shown to enhance the expression of G9a mRNA and protein in NC and HP
tissues. This resulted in enhanced dimethylation of H3K9 and H3K27 followed by caspase-3 mediated
degradation of these proteins. Further studies using G9a (Bix 01294), as well as caspase-3 (Q-VD-Oph)
inhibitors, have suggested that the activation of G9a results in robust neurodegeneration in neonatal
mice and deficits in synaptic plasticity and learning and memory in adult mice [6,213] as observed
in FASD children [193,195,198]. These neurobehavioral impairments were rescued by preventing the
alcohol activated G9a [213]. Similarly, alcohol also enhanced the transcriptional activity of cannabinoid
receptor 1 (CB1R) through promoter (exon1) specific enrichment of H4K8ace protein in the mouse NC
and HP. Transcriptional activation of CB1R results in impaired CB1R-mediated signal transduction
(pERK1/2/pCREB/activity-regulated cytoskeletal protein (Arc)), resulting in neurodegeneration in
neonatal mice and learning and memory deficits in adult mice [4,247]. These neurobehavioral deficits
were prevented by CB1R antagonist or CB1R knockout mice [4,247]. Furthermore, a promoter specific
analysis of histone H3 proteins using low dose alcohol (elicit mild neurodegeneration) showed an
enhanced specific acetylation of H3K14 and no change in H3K9me2 or H4K8ace levels, as observed in
the G9a exon1 region [5]. Transcriptional activation of G9a results in increased expression of the G9a
gene and protein, thereby resulting in enhanced global dimethylation of H3K9 and H3K27 proteins
without any significant degradation of H3 proteins due to the low activity of caspase-3, as found in
a low-dose alcohol model [5]. In another prenatal alcohol model, alcohol was shown to enhance the
expression of genes that have a role in the fetal heart through promoter-specific H3K14 acetylation
in mice [267]. In a similar fetal heart study, alcohol increased global HAT activity without affecting
global HDAC activity. Additionally, alcohol increased the binding of P300, CBP, PCAF, SRC1, but
not GCN5, at the Gata4 promoter region in comparison to the saline-treated group. The increases in
acetylation of H3K9, as well as in Gata4, α-myosin heavy chain (α-MHC) and cardiac troponin T (cTnT)
mRNA levels, were also evident in these fetal hearts [268]. Studies in a prenatal alcohol model suggest
that alcohol enhanced the enrichment of histone H3K4me3 at the Slc17a6 promoter, which encodes
VGLUT2 [249]. Acute exposure to alcohol at GD 7 in mice exhibit significantly increased H3K9me2
and H3K9ace levels and reduced H3K27me3 levels at GD 17 and that these histone modifications
strongly correlate with the development of craniofacial and CNS defects in this animal model. These
observations indicate that an epigenetic signature persists long after the window of alcohol exposure
and is mostly linked to alterations in a repressive chromatin structure, such as H3K9me2 [162].
The first evidence of histone acetylation modification by developmental alcohol was found in
cardiac progenitor cells where alcohol enhanced H3K9ace and augmented the mRNA expression of
heart development-related genes [224]. Exposure to alcohol during the third trimester-equivalent
of human pregnancy reduces CBP levels, followed by reduced histones H3 and H4 acetylation in
the neonatal cerebellum [222]. Prenatal alcohol exposure enhanced long-lasting H3K9ace marks and
CBP mRNA levels in β-endorphin (BEP)-positive cells in the ARC of the hypothalamus of male rat
offspring [221]. The transient exposure of immature P7 mice to alcohol, which is comparable with
a time point within the third trimester of human pregnancy, enhances specific acetylation of H3K14
in the G9a exon1 gene, which results in enhanced G9a transcription [5]. In a similar mouse model,
it was shown that alcohol enhances acetylation of H4K8 in the CB1R exon1 gene, thereby leading to
enhanced CB1R expression and impaired synaptic plasticity, learning and memory in adult mice [4].
Prenatal alcohol exposure reduced both mRNA levels of KMT7/9 (Set7/9) and the number
of H3K4me2, 3-positively stained BEP cells. Additionally, enhanced KMT1C (G9a) and KMT1F
(Setdb1) mRNA, as well as H3K9me2-positively stained BEP cells, was observed in the ARC of the
hypothalamus of rat offspring exposed to prenatal alcohol [221]. In another study, binge-like alcohol
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exposure in P7 mice, which is comparable with the third trimester of human pregnancy, enhanced
KMT1C (G9a) expression, as well as in H3K9me2 and H3K27me2, in both neocortical and hippocampal
tissues of neonatal mice [5]. This particular dimethylation of both histones marks them for proteolytic
degradation by activated caspase-3 in this animal model [6]. The inhibition of KMT1C (G9a) activity
before alcohol treatment not only rescued neurodegeneration in neonatal mice but also synaptic
plasticity and learning memory in adult mice [213]. Gestational choline treatment, which has been
shown to prevent pre/postnatal alcohol-induced learning and memory [244,269], also normalized
the alcohol-suppressed hypothalamic levels of H3K4me3, as well as the NA levels of KMT7/9, and
increased the H3K9me2 and mRNA levels of KMT1C and KMT1F in the hypothalamus of adult male
offspring rats [220]. In another study, prenatal alcohol exposure enhanced SLC17A6 gene expression,
which codes for VGLUT2 through the enrichment of H3K4me3 at the SLC17A6 promoter region
in adult mice [249]. In another study, acute exposure of GD7 mice to alcohol significantly disrupts
transcripts that encode for KMT1C (G9a), KMT6 (EzH2) and KMT7 (SETdB1) proteins [162]. Together,
these findings suggest that these epigenetic mechanisms (Table 2) may have a direct role in cognitive
dysfunction observed in FASD.
Table 2. Influence of developmental alcohol on histone modifications.
Alcohol Exposure Tissue Examined Effects
1. Gestational Day (GD) 7 GD 17
Increased H3K9me2, H3K9ace and decreased H3K27me3 [162]
Altered G9a, Setdb1, Kdm1a, Kdm4c, Uhrf1, Ezh2 and Dnmt1
mRNA levels [162]
2. Postnatal Days (PD) 2–12 PD 2–12 Decreased AcH3, AcH4, H3K23ace and increased HAT(CBP) [222]
3. GD 7–21 PD 60–80 from F1–F3 generation
Decreased H3K4me2, H3K4me3, H3K9ace, pH3S10 and
mRNA Set7/9 [220]; Increased mRNA G9a, setdb1
H3K9me2 [220]
Decreased H3K4me2,H3K4me3, H3K9ace and
Decreased mRNA levels of Set7/9; Increased G9a mRNA
H3K9me2 and HDAC2 [221]
4. GD 1–14.5 Embryonic days (ED) 7.0–14.5 Increased H3K14ace [267]
5. PD 7 PD 7
Increased H4K8ace [4], H3K14ace [5]
Decreased H3K9me2, H3K27me2 [4]
Decreased H3K9me2, H3K27me2 [6],
H3K9me2 [213]
Increased G9a mRNA and Protein [6]
6. ED 8.5–E16.5 ED14.5–PD 7 Increased p300 and SRC1 protein. No Change in HDAC.Increased HAT (CBP and PACF) [268]
7. ED 8.5–16.5 ED 14.5–16.5 Increased H3K14ace [267]
8. Days of post cotium (dpc)
0.5–8.5 PD 87 Increased H3K4me3 and Slcl7a6 gene expression [249]
PD, Postnatal day; GD, Gestational day; ED, Embryonic day; dpc, days post coitum; H3K9me2, Histone3
lysine 9 methylation; H3K27me2, histone 3 lysine 27 dimethylation; H3K9ace, Histone 3 lysine 9 acetylation;
H3K14ace, Histone 3 lysine14 acetylation; H4K8ace, Histone 4 lysine 8 acetylation; H3K4me2, Histone3
lysine4 dimethylation; H3K4me3, Histone3 lysine4 trimethylation; AcH3, Acetylated histone3; AcH4,
Acetylated Histone 4; Uhrf1, Ubiquitin-like protein containing phd and ring finger domains 1; G9a,
Histone methyltransferase; Ezh2, Enhancer of zeste 2 polycomb repressive complex 2 subunit; HAT, Histone
acetyltransferases; Dnmt1, DNA methyltransferase 1; SRC-1, Steroid receptor coactivator-1; HDAC, Histone
deacetylases; CBP, cAMP response element-binding protein binding protein; PACF, p300/CBP-associated factor;
Set7/9, Set domain histone lysine methyltransferases; Setdb1, Set domain bifurcated1; pH3S10, phosphorylated
H3 at serine 10; Slcl7a6, Solute Carrier Family 17 (Vesicular Glutamate Transporter), Member 6.
The first evidence to show that early alcohol alters miRNA (Table 3) was shown in NSCs using
ex vivo fetal cerebral cortical neuroepithelium model [228]. In this study, alcohol, which was shown to
promote cell proliferation and aberrant differentiation, did not cause the death of NSCs, but rather
suppressed miR-9, -21, -153, and -335 levels [228]. Furthermore, it has been shown that the lack of
cell death by alcohol in this study was due to the combined loss of miR-335 and miR-21 and the loss
of miR-335 alone was responsible for the increased NSC proliferation in response to alcohol [228].
In another study using a prenatal mouse model, it has been shown that alcohol increased certain
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miRNAs (miR-10a, -10b, -9, -145, -30a-3p and miRNA-152) and decreased other miRNAs (miR-200a,
-496, -296, -30e-5p, -362, -339, -29c and -154) in the fetal brain. This resulted in impaired task acquisition
in the Morris water maze in P35 mice [231].
Table 3. Summary of the developmental alcohol elicited changes in miRNAs.
Alcohol Exposure Tissue Examined Effects
1. GD 12.5 Neurosphere cultures Reduced the expression of miR-9, 21, 335 and -135 [228]
2. GD 6–15 GD 17 embryo culture Increased miR-10a, -9, -145, -30a-3p and -152. Also decreasedmiR-200a, -496, -296, -30e-5p, -362, -339, -29c and -154 [231]
3. Zebrafish Embryos (4–96 hpf) Enhanced miR-153a, -30d, -736, -183 and reduced -23a [229]
4. GD 12.5 Neurosphere cultures Reduced the expression of miR-140-3p [225]
5. PD 7 PD 60 Increased expression of miR-26b [230]
6. Zebrafish Embryos (24–72 hpf) Suppressed miR-9a and increased the accumulation ofpre-miR-9-3 [270]
7. PD 7 PD 60 Enhanced miR-302c [271]
8. GD 1–22 PD 42
Decreased miR-874-5p, 1843a-3p, -221-5p, -29c-3p, -384-5p,
-412-3p, 129-1, -138-2, -322-2, -496, -9a-2. Increased miR-155,
-34c, -let-7c-1, -let-7c-2-3p, -542-1 [272]
9. GD 0.5–8.5 PD 87 Enhanced miR-135a, -135b, -467b-5b and -487b [249]
10. GD 4–132 (Ewes) Plasma (GD 147) Decreased miR-572, -720, -9, -15b, -17-92 and increasedmiR-34b [273]
hpf, hours post fertilization; GD, gestational day; PD, postnatal day.
In another study, Zebrafish embryos were exposed to alcohol, which was then followed by the
evaluation of miRNA levels and deformation. This study showed increases in miR-153a, -725, -30d,
let-7k, -100, -738, and -732 and decreases in miR-128 and -193b and induced cell death along the dorsal
axis of the embryo [229]. In another study, using P7 mouse model of FASD, alcohol was shown to
enhance miR-26b levels in adult whole brain tissues [230]. MicroRNA-26b, which is implicated in
the differentiation of NSCs [227], has also been shown to control the expression of genes that encode
for brain-derived neurotrophic factor (BDNF), which is important for neurodevelopment [226,227].
Exposure of GD12.5 mouse fetal murine cerebral cortical-derived neurosphere cultures to alcohol
suppressed the expression of several miRNAs, including miR-9, -21, -153, and -335, as well as
miR-140-3p [225]. In Zebrafish embryos, alcohol suppresses miR-9 biogenesis. This early embryonic
loss of miR-9 function recapitulates the severe range of teratology that is associated with early alcohol
exposure [270]. In another study that uses an acute prenatal model (second-trimester equivalent),
alcohol was shown to enhance miR-302c in the adult whole brain [271]. MicroRNA-302 is suggested to
have a critical function in neural tube closure and embryonic survival [274]. Furthermore, rats treated
with acute alcohol at GD 12 exhibit both upward and downward changes in several miRNAs in the
amygdala and ventral striatum in association with decreased social motivation behavior at P42 [272].
Social enrichment of GD12 alcohol-exposed rats rescued both miRNA and social motivation behavior in
P42 mice [272]. Furthermore, it has been shown that miR-125b can rescue alcohol-induced apoptosis in
NCCs by decreasing the expression of Bcl-2 antagonist killer 1 (BAK1) and p53-upregulated modulator
of apoptosis (PUMA) genes (pro-apoptotic genes). Additionally, the microinjection of miR-125b mimic
into cultured mouse embryos prevented alcohol-induced embryotoxicity [275]. Prenatal exposure
of mice on GD1-8 resulted in enhanced miR-135a, -135b, -467b-5p and -487b in the P87 murine
hippocampus. Additionally, miR-467b-5p and the 31UTR of Slc17a6 exhibited specific interactions
in vitro and suggested that a similar interaction in vivo may contribute to reduced HP VGLUT2 protein
levels in alcohol-exposed adult males [249]. In this model, alcohol not only enhanced HP levels of
miRNAs but also increased miRNAs, miR-135a, miR-135b and miR-467b-5p levels in the serum [249].
These findings suggest that miRNA may have an important role in HP dysfunction found in FASD
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and circulating miRNAs could be used as biomarkers of early developmental alcohol exposure [249].
A similar change in circulating miRNAs (miR-9, -15b, -19b, and -20a) was also found in pregnant ewes
and in newborn lambs (GD 147) that were exposed to alcohol between GD 4 and GD 132 [273]. Alcohol
exposure in P7 mice was shown to alter several miRNA transcripts and was found to be associated
with genes that are important for neural connectivity [276] and may contribute to cognitive deficits, as
found in FASD children.
4. Conclusions
In summary, several epigenetic mechanisms are suggested to contribute to the harmful
consequences of alcohol abuse during pregnancy in the developing fetus (Figure 5). Epigenetic
modifications, such as altered DNA methylation, specific histone protein modification and
dysregulation of miRNA, in response to developmental alcohol exposure, can contribute to impaired
neurogenesis, neuronal communication and neural circuit assembly. These alcohol-induced neuronal
deficits can be long-lasting and could result in abnormalities in synaptic plasticity and cognitive
function and can provide bases for many of the neurobehavioral abnormalities found in FASD. The
broad role of DNA methylation and chromatin modification in learning and memory has not been
fully understood. This is because learning and memory is regulated by a dynamic interplay between
the various signaling molecules, enzymes and proteins that are capable of modifying the chromatin
structure. Additionally, there is a lack of understanding of the mechanisms that both predicate and
result from epigenetic modifications that regulate learning and memory process. Modulation of
epigenetic marks using pharmacological and gene knock-in or knockout approaches support a role for
the epigenetic process in learning and memory, therefore making it a promising target for the future
development of potential therapeutic agents to treat FASD.
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